blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3518962

EP3518962 - SEBELIPASE ALFA FOR USE IN LIVER FIBROSIS AND TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS BASED ON ISHAK FIBROSIS STAGE [Right-click to bookmark this link]
Former [2019/32]METHODS FOR REDUCING LIVER FIBROSIS AND TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS BASED ON ISHAK FIBROSIS STAGE
[2021/12]
StatusNo opposition filed within time limit
Status updated on  15.04.2022
Database last updated on 27.07.2024
FormerThe patent has been granted
Status updated on  11.05.2021
FormerGrant of patent is intended
Status updated on  15.03.2021
FormerRequest for examination was made
Status updated on  05.07.2019
FormerThe international publication has been made
Status updated on  07.04.2018
Formerunknown
Status updated on  08.11.2017
Most recent event   Tooltip03.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 05.06.2024  [2024/23]
Applicant(s)For all designated states
Alexion Pharmaceuticals, Inc.
121 Seaport Boulevard
Boston, MA 02210 / US
[2019/32]
Inventor(s)01 / QUINN, Anthony
21 Fort Hill Ave.
Gloucester MA 01930 / US
02 / GOODMAN, Zachary
3300 Gallows Road
Falls Church VA 22042 / US
03 / BURTON, Barbara
420 E. Superior Ave.
Chicago IL 60611 / US
04 / RANKIN, Andrew
121 Seaport Boulevard
Boston MA 02110 / US
05 / FRIEDMAN, Mark
230 Upland Ave.
Newton MA 02461 / US
06 / SONI, Paresh
148 Long Wharf Drive
Mystic CT 06355 / US
 [2019/36]
Former [2019/32]01 / QUINN, Anthony
21 Fort Hill Ave.
Gloucester MA 01930 / US
02 / GOODMAN, Zachary
3300 Gallows Road
Falls Church VA 22042 / US
03 / BURTON, Barbara
420 E. Superior Ave.
Chicago IL 60611 / US
04 / RANKIN, Andrew
66 Quarry Dock Road
Branford CT 06405 / US
05 / FRIEDMAN, Mark
230 Upland Ave.
Newton MA 02461 / US
06 / SONI, Paresh
148 Long Wharf Drive
Mystic CT 06355 / US
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2021/23]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2019/32]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date17791485.028.09.2017
[2019/32]
WO2017US53961
Priority number, dateUS201662402183P30.09.2016         Original published format: US 201662402183 P
US201662420233P10.11.2016         Original published format: US 201662420233 P
US201762456511P08.02.2017         Original published format: US 201762456511 P
[2019/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018064303
Date:05.04.2018
Language:EN
[2018/14]
Type: A1 Application with search report 
No.:EP3518962
Date:07.08.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 05.04.2018 takes the place of the publication of the European patent application.
[2019/32]
Type: B1 Patent specification 
No.:EP3518962
Date:09.06.2021
Language:EN
[2021/23]
Search report(s)International search report - published on:EP05.04.2018
ClassificationIPC:A61K38/46, A61P1/16, A61P3/00
[2019/32]
CPC:
A61K38/465 (EP,US); A61K9/0019 (US); A61P1/16 (EP,US);
A61P3/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/32]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:SEBELIPASE ALFA ZUR REDUZIERUNG VON LEBERFIBROSE UND BEHANDLUNG VON MORBUS WOLMAN AUF BASIS DES ISHAK-FIBROSEGRADS[2021/13]
English:SEBELIPASE ALFA FOR USE IN LIVER FIBROSIS AND TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS BASED ON ISHAK FIBROSIS STAGE[2021/12]
French:SEBELIPASE ALFA POUR LE RÉDUCTION DE LA FIBROSE HÉPATIQUE ET DU TRAITEMENT D'UN DÉFICIT EN LIPASE ACIDE LYSOSOMALE SUR LA BASE D'UN STADE DE FIBROSE D'ISHAK[2021/12]
Former [2019/32]VERFAHREN ZUR REDUZIERUNG VON LEBERFIBROSE UND DES MANGELS AN LYSOSOMALER SAURER LIPASE IN PATIENTEN AUF BASIS DER ISHAK-FIBROSE-STUFE
Former [2019/32]METHODS FOR REDUCING LIVER FIBROSIS AND TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS BASED ON ISHAK FIBROSIS STAGE
Former [2019/32]PROCÉDÉS DE RÉDUCTION DE LA FIBROSE HÉPATIQUE ET DE TRAITEMENT D'UNE DÉFICIENCE EN LIPASE ACIDE LYSOSOMALE CHEZ DES PATIENTS SUR LA BASE D'UN STADE DE FIBROSE ISHAK
Entry into regional phase01.04.2019National basic fee paid 
01.04.2019Designation fee(s) paid 
01.04.2019Examination fee paid 
Examination procedure01.04.2019Examination requested  [2019/32]
01.04.2019Date on which the examining division has become responsible
15.11.2019Amendment by applicant (claims and/or description)
16.03.2021Communication of intention to grant the patent
04.05.2021Fee for grant paid
04.05.2021Fee for publishing/printing paid
04.05.2021Receipt of the translation of the claim(s)
Opposition(s)10.03.2022No opposition filed within time limit [2022/20]
Fees paidRenewal fee
01.04.2019Renewal fee patent year 03
28.09.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.09.2017
AL09.06.2021
CY09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
MK09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
LU28.09.2021
IS09.10.2021
PT11.10.2021
[2024/23]
Former [2023/33]HU28.09.2017
AL09.06.2021
CY09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
LU28.09.2021
IS09.10.2021
PT11.10.2021
Former [2023/30]AL09.06.2021
CY09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
LU28.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/34]AL09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
LU28.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/29]AL09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SI09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/25]AL09.06.2021
CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
MC09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/21]CZ09.06.2021
DK09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/10]CZ09.06.2021
EE09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
IS09.10.2021
PT11.10.2021
Former [2022/09]CZ09.06.2021
FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
RO09.06.2021
RS09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
PT11.10.2021
Former [2022/07]FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
RS09.06.2021
SM09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
Former [2021/51]FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
RS09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
Former [2021/49]FI09.06.2021
HR09.06.2021
LT09.06.2021
LV09.06.2021
BG09.09.2021
NO09.09.2021
GR10.09.2021
Former [2021/47]FI09.06.2021
LT09.06.2021
BG09.09.2021
Former [2021/46]FI09.06.2021
LT09.06.2021
Cited inInternational search[AD]WO2011133960  (SYNAGEVA BIOPHARMA CORP [US], et al) [AD] 1-22* claims 1-72 *;
 [XI]  - BARBARA K. BURTON ET AL, "A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM -, US, (20150910), vol. 373, no. 11, doi:10.1056/NEJMoa1501365, ISSN 0028-4793, pages 1010 - 1020, XP055440916 [X] 1-11,13,17-22 * abstract;; figures 1-2; table 2 * [I] 1-22

DOI:   http://dx.doi.org/10.1056/NEJMoa1501365
 [XI]  - MANISHA BALWANI ET AL, "Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients With cholesteryl ester storage disease", HEPATOLOGY, (20130901), vol. 58, no. 3, doi:10.1002/hep.26289, ISSN 0270-9139, pages 950 - 957, XP055399555 [X] 1-11,13,15,17-22 * abstract;; figures 1-3 * [I] 1-22

DOI:   http://dx.doi.org/10.1002/hep.26289
 [XI]  - VALAYANNOPOULOS VASSILI ET AL, "Sebelipase alfa over 52weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency", JOURNAL OF HEPATOLOGY, (2014), vol. 61, no. 5, doi:10.1016/J.JHEP.2014.06.022, ISSN 0168-8278, pages 1135 - 1142, XP029077680 [X] 1-11,13,15,17-22 * abstract;; figures 1-5; tables 1-2 * [I] 1-22

DOI:   http://dx.doi.org/10.1016/j.jhep.2014.06.022
by applicantUS7524626
 WO2011133960
    - Scriver, C. R., Beaudet, A. L., Sly, W. S. and Valle D.,, The Metabolic and Molecular Bases of Inherited Disease 7th ed.,, McGraw-Hill, (19950000), vol. 2, page 2570
    - DI BISCEGLIE et al., Hepatology, (19900000), vol. 11, pages 764 - 772
    - AMEIS et al., J. Lipid Res., (19950000), vol. 36, pages 241 - 250
    - DU BOIS D; DU BOIS EF, Archives of Internal Medicine, (19160600), vol. 17, no. 6, pages 863 - 71
    - VERBRAECKEN, J. et al., Metabolism — Clinical and Experimental, (20060400), vol. 55, no. 4, pages 515 - 24
    - MOSTELLER RD., N Engl J Med.,, (19870000), vol. 317, page 1098
    - HAYCOCK GB et al., et al., J Pediatr, (19780000), vol. 93, pages 62 - 66
    - GEHAN EA; GEORGE SL, Cancer Chemother Rep, (19700000), vol. 54, pages 225 - 235
    - CURRENT, JD, The Internet Journal of Anesthesiology, (19980000), vol. 2, no. 2
    - FUJIMOTO S et al., Nippon Eiseigaku Zasshi, (19680000), vol. 5, pages 443 - 50
    - SCHLICH E et al., Ernahrungs Umschau, (20100000), vol. 57, pages 178 - 183
    - E. MEYERS; W. MILLER, Comput. Appl. Biosci., (19880000), vol. 4, pages 11 - 17
    - NEEDLEMAN; WUNSCH, J. Mol, Biol., (19700000), vol. 48, pages 444 - 453
    - GOODMAN, Journal of Hepatology, (20070000), vol. 47, pages 598 - 607
    - ISHAK et al., Journal or Hepatology, (19950000), vol. 22, pages 696 - 699
    - R A STANDISH et al., Gut, (20060000), vol. 55, pages 569 - 578
    - BURTON et al., Clinica Chimica Acta, (19800000), vol. 101, pages 25 - 32
    - ANDERSON et al., Mol. Genet. & Metab., (19990000), vol. 66, pages 333 - 345
    - FOLCH et al., J. Biol. Chem, (19570000), vol. 226, pages 497 - 505
    - DU et al., Am. J. Hum. Genet., (20050000), vol. 77, pages 1061 - 1074
    - DU et al., J. Lipid Res., (20080000), vol. 49, pages 1646 - 1657
    - MEYERS; MILLERS, Computer Applic. Biol. Sci., (19880000), vol. 4, pages 11 - 17
    - SMITH; WATERMAN, "2", Adv. Appl. Math., (19810000), page 482
    - NEEDLEMAN; WUNSCH, J. Mol. Biol., (19700000), vol. 48, page 443
    - PEARSON; LIPMAN, Proc. Natl. Acad. Sci. U.S.A., (19880000), vol. 85, page 2444
    - ALTSCHUL et al., Nucl. Acids Res., (19970000), vol. 25, pages 3389 - 402
    - FENG; DOOLITTLE, J. Mol. Evol., (19870000), vol. 35, pages 351 - 360
    - HIGGINS; SHARP, CABIOS, (19890000), vol. 5, pages 151 - 3
    - HENIKOFF; HENIKOFF, Proc. Natl. Acad. Sci. U.S.A., (19920000), vol. 89, pages 10915 - 10919
 US20070973853
 US20070978360
 US20090319396
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.